CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫效应细胞相关神经毒性综合征(ICANS)是CAR-T 细胞治疗后的常见并发症。
本研究评估输注前脑电图(EEG)异常以及 ICANS 起病时 EEG 表现,在预测 56 例接受 CAR-T 治疗的难治性淋巴瘤成人患者 ICANS 风险和严重程度方面的作用。 研究设计:在淋巴细胞清除化疗期间及 ICANS 起病后不久进行 EEG。
28 例(50%)患者发生 ICANS,中位发生时间为 CAR-T 输注后 6 天。输注前 EEG 异常是严重 ICANS 的危险因素(50% 对 17%,P=0.036)。ICANS 起病后,89% 患者检测到 EEG 异常,包括脑病(n=19,70%)和/或发作间期癫痫样放电(IED,n=14,52%)。值得注意的是,IED 似乎与 24 小时内 ICANS 快速进展至更高级别相关。
若能在大型患者队列中证实,这些发现可为修订现行管理指南奠定基础,帮助识别神经毒性风险患者,并支持对神经毒性起病时为 1 级 ICANS 且伴 IED、可能发生神经功能损伤的患者预先使用皮质类固醇。
Immune effector cell-associated neurotoxicity syndrome (ICANS) is common after chimeric antigen receptor T-cell (CAR-T) therapy.
This study aimed to assess the impact of preinfusion electroencephalography (EEG) abnormalities and EEG findings at ICANS onset for predicting ICANS risk and severity in 56 adult patients with refractory lymphoma undergoing CAR-T therapy. STUDY DESIGN: EEGs were conducted at the time of lymphodepleting chemotherapy and shortly after onset of ICANS.
Twenty-eight (50%) patients developed ICANS at a median time of 6 days after CAR-T infusion. Abnormal preinfusion EEG was identified as a risk factor for severe ICANS (50% vs. 17%, P = 0.036). Following ICANS onset, EEG abnormalities were detected in 89% of patients [encephalopathy (n = 19, 70%) and/or interictal epileptiform discharges (IEDs) (n = 14, 52%)]. Importantly, IEDs seemed to be associated with rapid progression to higher grades of ICANS within 24 h.
If confirmed in a large cohort of patients, these findings could establish the basis for modifying current management guidelines, enabling the identification of patients at risk of neurotoxicity, and providing support for preemptive corticosteroid use in patients with both initial grade 1 ICANS and IEDs at neurotoxicity onset, who are at risk of neurological impairment.
MEMBER ACCOUNT
登录成功会直接打开下一页。